Citizens JMP raised the firm’s price target on Spruce Biosciences (SPRB) to $259 from $254 and keeps an Outperform rating on the shares. Spruce remains on track to submit its biologics license application for Tralesinidase Alfa Enzyme Replacement Therapy for Sanfilippo Syndrome Type B in 1Q26, the analyst tells investors in a research note. The firm is impressed with management’s execution since its acquisition of TA-ERT.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SPRB:
- Spruce Biosciences Reports Q3 2025 Financial Results
- Spruce Biosciences reports Q3 EPS (14.58) vs. ($15.75) last year
- Spruce Biosciences files to sell 735K shares of common stock for holders
- Spruce Biosciences files $300M mixed securities shelf
- Spruce Biosciences upgraded to Outperform from Market Perform at Citizens JMP